OmniAb (OABI) Non-Current Deferred Tax Liability (2021 - 2026)
OmniAb (OABI) posted quarterly Non-Current Deferred Tax Liability of $1.2 million for Q1 2026, down 44.43% year-over-year from $2.2 million in Q1 2025, and up 56.31% quarter-over-quarter from $785000.0 in Q4 2025.
OmniAb (OABI) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
OmniAb (OABI) has reported Non-Current Deferred Tax Liability for 6 consecutive years, with $1.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Non-Current Deferred Tax Liability fell 44.43% year-over-year to $1.2 million; the TTM figure through Mar 2026 stood at $1.2 million (down 44.43% YoY), while the FY2025 annual figure was $785000.0, down 66.08% from the prior year.
- Non-Current Deferred Tax Liability climbed to $1.2 million in Q1 2026 per OABI's latest filing, from $785000.0 in the prior quarter.
- Across five years, Non-Current Deferred Tax Liability topped out at $38.1 million in Q4 2023 and bottomed at $785000.0 in Q4 2025.
- Historically, Non-Current Deferred Tax Liability has averaged $10.0 million across 5 years, with a median of $5.5 million in 2024.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability soared 78.6% — and 2024, when it slumped 93.93%.
- OmniAb's Non-Current Deferred Tax Liability stood at $21.3 million in 2022, then jumped by 78.6% to $38.1 million in 2023, then plunged by 93.93% to $2.3 million in 2024, then slumped by 66.08% to $785000.0 in 2025, then soared by 56.31% to $1.2 million in 2026.
- Business Quant data shows OABI's Non-Current Deferred Tax Liability at $1.2 million in Q1 2026, $785000.0 in Q4 2025, and $1.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | OmniAb | 491.42 Mn | 439.42 Mn | 12.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 882,000.00 |
| Jun 30, 2026 | 882,000.00 |
| Mar 31, 2026 | 1.23 Mn |
| Mar 31, 2026 | 1.23 Mn |
| Dec 31, 2025 | 785,000.00 |
| Dec 31, 2025 | 785,000.00 |
| Sep 30, 2025 | 1.17 Mn |
| Sep 30, 2025 | 1.17 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Jun 30, 2025 | 2.33 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Mar 31, 2025 | 2.21 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Dec 31, 2024 | 2.31 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Jun 30, 2024 | 6.84 Mn |
| Mar 31, 2024 | 8.74 Mn |
| Mar 31, 2024 | 8.74 Mn |